During this program, learners will increase their knowledge in the management of congenital adrenal hyperplasia (CAH) by familiarizing themselves with emerging treatments and new safety and efficacy data. Participants will have greater competence related to the unmet needs in managing classic CAH in adult patients, mechanisms of action and clinical data of new and emerging therapies for CAH, applying this data to select treatments, and identifying potential places in therapy of emerging agents.
This initiative is designed for endocrinologists (MDs, DOs), primary care physicians (PCPs), nurse practitioners
(NPs), physician assistants (PAs), pediatricians, and other healthcare professionals (HCPs) who treat, care for,
and/or support CAH.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Medscape. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00
AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
Please note that while other accrediting bodies accept AMA PRA Category 1
credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Anand Vaidya, MD, MMSc: Program Chair; Associate Professor of Medicine, Harvard Medical School, Director, Center for Adrenal Disorders, Brigham and Women's Hospital, Boston, MA
Richard J. Auchus, MD, PhD, FACE: The James A. Shayman and Andrea S. Kevrick Professor of Translational Medicine, Division of Metabolism, Endocrinology and Diabetes, Departments of Internal Medicine and Pharmacology Michigan Medicine, University of Michigan, Ann Arbor, MI
Phyllis W. Speiser, MD: Emeritus Professor of Pediatrics, Zucker School of Medicine at Hofstra Northwell, Hempstead, NY
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Anand Vaidya, MD, MMSc: Mineralys, Consultant; Grant Awardee, National Institutes of Health
Richard J. Auchus, MD, PhD, FACE: Corpect Therapeutics, Neurocrine Biosciences, Diurnal, Crinectics Pharmaceuticals, Recordati Rare Diseases, Contracted Research Support and Consultant; Sparrow Pharmaceuticals, Consultant; Spruce Biosciences, Adrenas Therapeutics, Contracted Research Support; Quest Diagnostics, Novo Norkisk, H. Lundbeck A/S, Xeris, OMass Therapeutics, US Anti-Doping Agency, Consultant; Cares Foundation, APS1 Foundation, Seal Future Foundation, Medical Advisory Board.
Phyllis W. Speiser, MD: IF CAH, Grant Revewer; Adrenas Therapeutics, DSMC Member; Chan Zuckerberg Rare as One, Scientific Advisory Board; LEK Consultanting, Lumanity Consulting, Consultant; Neurocrine CAH, Novo Norkisk, Advisory Board; Pharmatecture, WebMD, Speaker, Roche Diagnostics, Advisory Group.
The following faculty reported no relevant financial relationships:
N/A
The following committee member who planned and reviewed content for this activity reported no relevant financial relationships:
Ismat Shafiq, MD
The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.
The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.
Acknowledgement of Commercial Support:
This educational activity is supported by an educational grant from Neurocrine Biosciences.